thalidomide has been researched along with Peritoneal Carcinomatosis in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 6.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Celecoxib is a potent selective COX-2 inhibitor." | 5.32 | [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]. ( Hada, M; Kazuhiro, M, 2004) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 2.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Thalidomide was not more effective than tamoxifen in delaying recurrence or death but was more toxic." | 2.75 | Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation ( Benbrook, DM; Brady, MF; Darcy, KM; Edmonds, P; Hurteau, JA; Ivanov, I; Mannel, RS; McGuire, WP; Pearl, ML; Tewari, KS; Zanotti, K, 2010) |
| " The majority of adverse events were grades 1-2, including fatigue (25/80 cycles), nausea/vomiting (23/80), constipation (13/80), abdominal pain (17/80), rash (12/80), neutropenia (12/80), and anemia (12/80)." | 2.73 | Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. ( Chan, JK; Guo, HY; Husain, A; Teng, NN; Zhang, MM, 2007) |
| "Thalidomide is an anti-angiogenesis agent that has shown activity in some solid tumors." | 2.72 | Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. ( Chan, JK; Cheung, MK; Ciaravino, G; Husain, A; Manuel, MR; Teng, NN, 2006) |
| "Celecoxib is a potent selective COX-2 inhibitor." | 1.33 | [A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine]. ( Hada, M; Horiuchi, T; Shinji, H, 2006) |
| "Celecoxib is a potent selective COX-2 inhibitor." | 1.32 | [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]. ( Hada, M; Kazuhiro, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, P | 1 |
| Thomas, CR | 1 |
| Fenstermaker, J | 1 |
| Aklilu, M | 1 |
| McCoy, TP | 1 |
| Levine, EA | 1 |
| Gurung, S | 1 |
| Fu, H | 1 |
| Zhang, WW | 1 |
| Gu, YH | 1 |
| Hurteau, JA | 1 |
| Brady, MF | 1 |
| Darcy, KM | 1 |
| McGuire, WP | 1 |
| Edmonds, P | 1 |
| Pearl, ML | 1 |
| Ivanov, I | 1 |
| Tewari, KS | 1 |
| Mannel, RS | 1 |
| Zanotti, K | 1 |
| Benbrook, DM | 1 |
| Hada, M | 2 |
| Kazuhiro, M | 1 |
| Horiuchi, T | 1 |
| Shinji, H | 1 |
| Biswas, G | 1 |
| Narayanan, P | 1 |
| Bhagwat, R | 1 |
| Khadwal, A | 1 |
| Bakshi, AV | 1 |
| Parikh, PM | 1 |
| Chan, JK | 2 |
| Manuel, MR | 1 |
| Ciaravino, G | 1 |
| Cheung, MK | 1 |
| Husain, A | 2 |
| Teng, NN | 2 |
| Zhang, MM | 1 |
| Guo, HY | 1 |
| Calligaris, L | 1 |
| Marchetti, F | 1 |
| Ventura, A | 1 |
| Abramson, N | 1 |
| Stokes, PK | 1 |
| Luke, M | 1 |
| Marks, AR | 1 |
| Harris, JM | 1 |
1 review available for thalidomide and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Hepatic epithelioid hemangioendothelioma metastasized to the peritoneum, omentum and mesentery: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; | 2015 |
5 trials available for thalidomide and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Appendiceal Neoplasms; | 2014 |
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormo | 2010 |
Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; California; Drug Administration Schedule | 2006 |
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Neoplasm Recurrence, | 2007 |
Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Sero | 2002 |
4 other studies available for thalidomide and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Combined Modality Therapy; Dru | 2004 |
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration | 2006 |
Thalidomide in primary peritoneal mesothelioma.
Topics: Angiogenesis Inhibitors; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Thalidomide | 2006 |
Intestinal plexiform neurofibromas.
Topics: Angiogenesis Inhibitors; Child; Diagnosis, Differential; Female; Humans; Ileal Neoplasms; Mesentery; | 2008 |